#China #FDA #Wuxi #WuXi Biologics #GMP Inspection

WuXi Biologics Reinforces Quality and Reliability with FDA Approval

In a significant milestone for the biopharmaceutical industry, WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully passed an intensive two-week Good Manufacturing Practice (GMP) inspection by the U.S. Food and Drug Administration (FDA). Conducted at the company's Wuxi Mashan site, this inspection underscores WuXi Biologics' commitment to maintaining the highest standards in drug manufacturing, particularly in the U.S. market.

The FDA inspection scrutinized a variety of FDA-approved products manufactured at WuXi Biologics, including monoclonal antibodies, bispecific antibodies, fusion proteins, and various enzyme-based therapies. By passing this inspection, WuXi Biologics not only demonstrates its adherence to stringent regulatory requirements but also reinforces its strong track record in regulatory compliance.

A History of Excellence

WuXi Biologics' Wuxi Mashan facility holds a notable distinction: it was the first biopharmaceutical manufacturing site in China to receive approval from both the FDA and the European Medicines Agency (EMA) for commercial production. This pioneering facility seamlessly integrates drug substance (DS) and drug product (DP) manufacturing capabilities, thereby streamlining the entire process from technology transfer to commercial supply. This integration is pivotal in enhancing operational efficiency, enabling faster project execution, and supporting the global launch of new biologics.

Over its 13 years in operation, WuXi Biologics has achieved an impressive 100% success rate across more than 600 regulatory and client audits. This accomplishment showcases the company's robust quality management systems and operational excellence. The site has been instrumental in the global launch of over 20 biologics, highlighting its crucial role in advancing medical therapies worldwide.

CEO's Commitment to Quality

Dr. Chris Chen, the CEO of WuXi Biologics, expressed pride in the successful outcome of the FDA inspection, stating, "This accomplishment reaffirms our commitment to the highest standards of quality and operational excellence. Quality is a cornerstone of the trust our global partners place in us. As demand for commercial supply continues to grow, alongside evolving regulatory expectations, our dedication to reliable, high-quality manufacturing services remains unwavering.” He emphasized that through their quality systems and expanding capabilities, WuXi Biologics is striving to help partners deliver innovative therapies efficiently and effectively.

WuXi Biologics has consistently showcased its dedication to complying with rigorous industry quality standards. As of June 2026, the company has successfully passed 49 regulatory inspections, with 22 conducted by the FDA and EMA. Additionally, it has secured 166 facility license approvals and completed over 2,000 GMP quality audits by global clients, further solidifying its reputation in the biopharmaceutical sector. Their global manufacturing network comprises 26 drug substance facilities and 19 drug product facilities, each contributing to WuXi Biologics' esteemed status as a trustworthy partner in the industry.

Looking Ahead

WuXi Biologics continues to lead the way in not just operational excellence but also in sustainable practices. The company maintains a strong commitment to sustainability, driving technology innovations to provide advanced Green CRDMO solutions and upholding exemplary Environmental, Social, and Governance (ESG) practices.

WuXi Biologics stands poised to adapt to the growing demands of the pharmaceutical market, continuing to leverage its expertise and operational capacity to deliver tailored, efficient solutions. With a collaborative approach, they are dedicated to fostering positive impacts across the entire value chain, empowering stakeholders and ensuring reliable therapy delivery to patients across the globe.

For further insights about WuXi Biologics and its commitment to biopharmaceutical excellence, please visit WuXi Biologics' website.